HomeCancerProstate

Prostate

Merck and Orion Announce Mutual Train of Choice Offering Merck International Unique Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Therapy of Metastatic...

RAHWAY, N.J., July 01, 2024--(BUSINESS WIRE)--Merck (NYSE: MRK), referred to as MSD exterior of the US and Canada, and Orion Company ("Orion") at...

Staying alive – PharmaTimes

Staying alive  PharmaTimes

Leveraging Synthetic Intelligence Evolutions in Prostate Most cancers Care

In a dialog with CancerNetwork®, James B. Yu, MD, MHS, FASTRO, and Julian C. Hong, MD, MS, spoke about their research titled AI...

Tanya B. Dorff, MD, on Outcomes From Section 1 CAR T-Cell Remedy mCRPC Trial

Tanya B. Dorff, MD, professor within the Division of Medical Oncology and Therapeutics Analysis and division chief of the Genitourinary Illness Program at...

Hot Topics